We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim to Acquire NBE-Therapeutics for $1.5 billion, Adding to its Cancer Treatment Pipeline
Boehringer Ingelheim to Acquire NBE-Therapeutics for $1.5 billion, Adding to its Cancer Treatment Pipeline